Grifols (GRFS) Change in Intangibles (2010 - 2020)
Grifols' (GRFS) quarterly Change in Intangibles came in at -$28.9 million in Q1 2020, down 54.18% YoY from -$63.1 million in Q2 2019, and up 60.41% on a QoQ basis from -$73.0 million in Q4 2019.
Grifols (GRFS) Change in Intangibles (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Change in Intangibles data on file, last reported at -$28.9 million in Q1 2020.
- Quarterly Change in Intangibles fell 54.18% year-over-year to -$28.9 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$73.9 million (down 373.3% YoY) and the FY2021 annual result came in at -$77.5 million, up 17.67% from the prior year.
- Change in Intangibles improved to -$28.9 million in Q1 2020, from -$73.0 million in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of $46.8 million in Q4 2018 to a low of -$73.0 million in Q4 2019.
- A 5-year average of -$8.1 million and a median of $4.1 million in 2017 frame the typical range for Change in Intangibles.
- Annual changes were most pronounced in 2016 — Change in Intangibles slumped 854.1% — and 2018, when it surged 364.21%.
- Tracing GRFS's Change in Intangibles over 5 years: stood at $35.5 million in 2016, then fell by 15.11% to $30.1 million in 2017, then soared by 55.34% to $46.8 million in 2018, then tumbled by 256.18% to -$73.0 million in 2019, then jumped by 60.41% to -$28.9 million in 2020.
- The last three Change in Intangibles figures came in at -$28.9 million (Q1 2020), -$73.0 million (Q4 2019), and -$18.8 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 393.11 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -28.91 Mn |
| Mar 31, 2020 | -28.91 Mn |
| Dec 31, 2019 | -73.03 Mn |
| Dec 31, 2019 | -73.03 Mn |
| Mar 31, 2019 | -18.75 Mn |
| Mar 31, 2019 | -18.75 Mn |
| Dec 31, 2018 | 46.76 Mn |
| Dec 31, 2018 | 46.76 Mn |
| Jun 30, 2018 | -62.47 Mn |
| Jun 30, 2018 | -62.47 Mn |
| Mar 31, 2018 | 18.84 Mn |
| Mar 31, 2018 | 18.84 Mn |
| Dec 31, 2017 | 30.10 Mn |
| Dec 31, 2017 | 30.10 Mn |
| Jun 30, 2017 | 18.45 Mn |
| Jun 30, 2017 | 18.45 Mn |
| Mar 31, 2017 | 4.06 Mn |
| Mar 31, 2017 | 4.06 Mn |
| Dec 31, 2016 | 35.46 Mn |
| Dec 31, 2016 | 35.46 Mn |